Sharemaestro Newsreel

BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal

BTIG has downgraded Apogee Therapeutics Inc (NASDAQ:APGE) to Neutral from Buy after shareholders approved the company's acquisition by AbbVie Inc (NYSE:ABBV) for $10.9 billion, or $135.11 per share. This deal, which sees Apogee's stock trading near its 52-week high with a significant return, is …

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly has filed six lawsuits against U.S. companies for allegedly selling black-market versions of its experimental obesity drug, retatrutide, which is still in Phase 3 clinical trials and has not yet received regulatory approval. The company is targeting compounding pharmacies, medical spas, and …

Handelsbanken Fonder AB Sells 446,938 Shares of Bristol Myers Squibb Company $BMY

Daiwa Upgrades Merck & Co. to Outperform From Neutral, Adjusts PT to $143 From $120

Daiwa has upgraded Merck & Co. (MRK) from a "Neutral" rating to an "Outperform" rating, significantly increasing its price target to $143 from the previous $120. The article, published on MarketScreener, highlights this analyst recommendation as a key news item for the pharmaceutical company. …

G&S Capital LLC Makes New $1.58 Million Investment in Amgen Inc. $AMGN

G&S Capital LLC has made a new $1.58 million investment in Amgen Inc. by purchasing 4,359 shares in the second quarter. The medical research company recently exceeded quarterly earnings and revenue expectations, reporting $6.29 EPS and $10.05 billion in revenue. Amgen also declared a …

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

Eli Lilly is suing six companies for selling unapproved versions of its experimental weight-loss drug, retatrutide, in an effort to curb a growing illicit market. Despite the drug still being in clinical trials, promising results have led to widespread unauthorized sales by telehealth firms, …

Eli Lilly sues vendors accused of hawking versions of its experimental GLP-1

Eli Lilly has filed six lawsuits against wellness vendors, accusing them of illegally selling versions of its experimental weight-loss drug, retatrutide. The company aims to combat the illicit online sales of what it describes as a potent experimental GLP-1 drug. This action comes amidst …

Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide …

If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever

Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically …

Gilead refreshes ADC biomarker collab with Nucleai

Gilead Sciences has renewed its collaboration with Israel-based Nucleai to apply Nucleai's AI-powered Tissue Intelligence platform for spatial biomarker generation and translational insights in Gilead's antibody-drug conjugate (ADC) clinical development programs. Nucleai's platform analyzes large datasets of H&E and IHC images, integrating computational pathology, …

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Eli Lilly and Company has filed six new lawsuits and escalated its fight against the illegal black market for retatrutide, an investigational drug not yet approved for human use. The company urges social media platforms, e-commerce sites, payment processors, and regulators to collaborate in …

The Manufacturers Life Insurance Company Lowers Position in Sanofi $SNY

The Manufacturers Life Insurance Company significantly reduced its stake in Sanofi by 58.9% in the first quarter of 2026, selling over 33,000 shares. Despite this, other institutional investors like Assetmark, QRG Capital Management, and Evergreen Capital Management increased their holdings in the pharmaceutical company. …

AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD

Amgen (NASDAQ: AMGN) announced its plan to open a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global R&D network. This new center aims to integrate experimental science with data and technology to accelerate the discovery and development of innovative medicines. …

Annex Advisory Services LLC Sells 5,431 Shares of Johnson & Johnson $JNJ

Annex Advisory Services LLC decreased its stake in Johnson & Johnson by 16%, selling 5,431 shares and retaining 28,619 shares valued at $7.27 million. This comes as Johnson & Johnson reported strong second-quarter results with revenue up 6.6% to $25.31 billion and adjusted EPS …

Assenagon Asset Management S.A. Boosts Holdings in Bristol Myers Squibb Company $BMY

Cardinal Capital Management Inc. Buys 21,206 Shares of AbbVie Inc. $ABBV

Cardinal Capital Management Inc. increased its stake in AbbVie Inc. by 8.4% during the second quarter, purchasing an additional 21,206 shares to bring its total holdings to 273,719 shares valued at approximately $68.9 million. Institutional investors collectively own 70.23% of ABBV, and analysts maintain …

Diversified Management Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ

Diversified Management Inc. significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) by 61.1% in the second quarter, selling 12,147 shares and leaving its holdings valued at $1.96 million. This comes as Johnson & Johnson reported stronger-than-expected Q2 earnings and raised its full-year outlook, …

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System significantly increased its stake in Organon & Co. ($OGN) by 34.8% in the first quarter, bringing its total holdings to 327,075 shares valued at approximately $1.96 million. Despite institutional investors collectively owning 77.43% of the company, analyst sentiment remains …

Merck & Company, Inc. Stock 12‑Month Price Target Raised to $138.29, Implies 6% Upside

Merck & Company, Inc. (MRK) has seen its average 12-month price target raised from $137.56 to $138.29 by 24 analysts, indicating a potential 6% upside from its Aug. 11 closing price. The consensus rating for the stock remains "Buy" among 29 analysts, with a …

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. …

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …

Pfizer (PFE) Agrees To $44 Million Class Action Settlement

Pfizer has agreed to a US$44 million class action settlement concerning its Chantix smoking cessation drug, addressing allegations of undisclosed carcinogenic nitrosamines. This settlement is considered small relative to Pfizer's substantial revenue, fitting within existing regulatory and product liability risk frameworks rather than introducing …

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". Profits are …

GODSEY & GIBB, INC's AbbVie Inc(ABBV) Holding History

GODSEY & GIBB, INC holds 74,257.00 shares of AbbVie Inc (ABBV) as of June 30, 2026, valued at $18.69 million, representing 1.53% of their stock portfolio. The firm's initial trade was in Q2 2021, and they have made 9 purchases and 9 sales of …

AstraZeneca PLC (AZN) News, Articles, Events & Latest Updates

This article provides a compilation of recent news and updates concerning AstraZeneca PLC (AZN). Key topics include options market movements, hedge fund bullishness, and reports of potential acquisition talks with Bristol Myers Squibb. It also covers related pharmaceutical news such as Merck's performance and …

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ: GILD) has significantly outpaced the market over the past two decades, yielding an average annual return of 11.31%. An initial investment of $1000 in GILD stock 20 years ago would now be valued at $8,488.28. This performance highlights the substantial impact …

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T

TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

This article compares AbbVie and CVS Health as investment opportunities in 2026, highlighting their distinct business models and risk profiles. AbbVie, a biopharmaceutical giant, is favored for its focused operations and exciting growth trajectory, particularly with its immunology portfolio. CVS Health, an integrated healthcare …

Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld

Gilead Sciences, Inc.'s EVP, Keeley M Cain Wettan, reported the conversion of 6,002 restricted stock units (RSUs) into common stock on August 10, 2026. Of these, 2,908 shares were withheld at $133.06 per share to cover exercise price or tax liability. Following this transaction, …

Pfizer Inc. stock underperforms Tuesday when compared to competitors

Pfizer Inc. (PFE) stock fell by 1.59% on Tuesday, closing at $26.62, and underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw declines. This drop ended a seven-day winning streak for the stock. The article highlights Pfizer's …

Biogen Inc. stock underperforms Tuesday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 1.56% to $203.89 on Tuesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marked the second consecutive day of losses for Biogen's stock.

aTyr, Biogen, City name legal chiefs

Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their …